Recent CARM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 11:06:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:32:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:21 PM
- Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders • PR Newswire (US) • 06/13/2024 08:30:00 PM
- Information Concerning the Total Number of Voting Rights and Share • Business Wire • 06/05/2024 03:45:00 PM
- Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers • Business Wire • 06/05/2024 03:45:00 PM
- Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 11:30:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/28/2024 11:39:56 PM
- Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:52:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:41:02 AM
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 05/09/2024 11:30:00 AM
- Carmila: Réduction des moyens du contrat de liquidité • Business Wire • 05/08/2024 03:45:00 PM
- Carmila: Withdrawal of funds for the liquidity contract • Business Wire • 05/08/2024 03:45:00 PM
- Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 • PR Newswire (US) • 05/08/2024 11:30:00 AM
- Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers • Business Wire • 05/07/2024 03:45:00 PM
- Information Concerning the Total Number of Voting Rights and Share • Business Wire • 05/07/2024 03:45:00 PM
- Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference • PR Newswire (US) • 05/06/2024 11:30:00 AM
- Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer • PR Newswire (US) • 05/02/2024 11:30:00 AM
- Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting • PR Newswire (US) • 04/24/2024 09:05:00 PM
- Carmila : Lancement d’un programme de rachat d’actions pour 10 millions d’euros • Business Wire • 04/24/2024 04:43:00 PM
- Carmila: Launch of a Share Buyback Program for €10 Million • Business Wire • 04/24/2024 04:43:00 PM
- Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting • PR Newswire (US) • 04/22/2024 08:35:00 PM
- Carmila : Information financière au 31 mars 2024 • Business Wire • 04/17/2024 03:45:00 PM
- Carmila: First-quarter 2024 Financial Information • Business Wire • 04/17/2024 03:45:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM